INTELLIGENCE BRIEF
The U.S. Food and Drug Administration (USFDA) granted multiple Abbreviated New Drug Application (ANDA) approvals between 03 and 10 September 2026, covering therapeutic areas including oncology, anticonvulsants, cardiovascular diseases, dermatology, pain management and hormonal therapy.
A total of 9 ANDA approvals were identified during this period, involving both established and specialized pharmaceutical products.
THERAPY AREA SNAPSHOT
- Oncology: Ibrutinib and Tivozanib
- Anticonvulsants: Brivaracetam and Topiramate
- Cardiovascular: Spironolactone + Hydrochlorothiazide
- Dermatology: Isotretinoin
- CNS / Wakefulness: Modafinil
- Pain Management: Tapentadol Hydrochloride
- Hormonal / Anabolic Therapy: Testosterone Cypionate
INTELLIGENCE TAKEAWAY
The week’s approvals demonstrate continued ANDA activity across both high-volume generic therapeutic categories and specialized products such as oncology and CNS medicines.
For regulatory and competitive intelligence teams, monitoring ANDA approvals can provide useful signals regarding:
- New generic market entrants
- Competitive activity by pharmaceutical companies
- Therapeutic areas experiencing increased generic development
- Potential changes in market competition
- Opportunities for product and portfolio intelligence
| Approval Date | Product Name | Dosage Form/Route | Manufacturer | Therapy Area | Approval Type |
| Sep 10, 2026 | Isotretinoin | Capsule; Oral | Aurobindo Pharma Ltd | Anti-acne agents | ANDA #220336 |
| Sep 10, 2026 | Spironolactone and Hydrochlorothiazide | Tablet; Oral | Rubicon Research | Antihypertensives | ANDA #220884 |
| Sep 8, 2026 | Ibrutinib | Capsule; Oral | Hetero Labs Ltd V | Anticancer – Chronic lymphocytic leukemia (CLL) | ANDA #211182 |
| Sep 8, 2026 | Brivaracetam | Tablet; Oral | Zhejiang Jutai Pharm | Anticonvulsants | ANDA #220136 |
| Sep 8, 2026 | Tivozanib | Capsule; Oral | Glenmark Pharmaceuticals Limited | Renal Cell Carcinoma | ANDA #220307 |
| Sep 4, 2026 | Topiramate | Capsule, Extended Release; Oral | Micro Labs | Anticonvulsants | ANDA #219183 |
| Sep 3, 2026 | Modafinil | Tablet; Oral; | Lupin | Wakefulness-promoting agents | ANDA #208343 |
| Sep 3, 2026 | Testosterone Cypionate | Intramuscular; Injection | Bpi Labs | Anabolic steroids | ANDA #219478 |
| Sep 3, 2026 | Tapentadol Hydrochloride | Tablet; Oral; Oral | Msn | Opioid analgesic | ANDA #220865 |